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In spite of aggressive surgery, irradiation and/or chemotherapy, treatment of malignant gliomas remains a major challenge in adults and
children due to high treatment failure. We have demonstrated significant cell lysis and antitumour activity of the E1B-55 kDa-gene-deleted
adenovirus ONYX-015 (dl1520, CI-1042; ONYX Pharmaceuticals) in subcutaneous human malignant glioma xenografts deriving from
primary tumours. Here, we show the combined efficacy of this oncolytic therapy with radiation therapy. Total body irradiation (5 Gy) of
athymic nude mice prior to intratumoral injections of ONYX-015 1 108 PFU daily for 5 consecutive days yielded additive tumour
growth delays in the p53 mutant xenograft IGRG88. Radiation therapy was potentiated in the p53 functional tumour IGRG121 with a
‘subtherapeutic’ dose of 1 107 PFU daily for 5 consecutive days, inducing significant tumour growth delay, 90% tumour regression and
50% tumour-free survivors 4 months after treatment. These potentiating effects were not due to increased adenoviral infectivity or
replication. Furthermore, cell lysis and induction of apoptosis, the major mechanisms for adenoviral antitumour activity, did not play a
major role in the combined treatment strategy. Interestingly, the oncolytic adenovirus seemed to accelerate radiation-induced tumour
fibrosis. Potentiating antitumour activity suggests the development of this combined treatment for these highly malignant tumours.
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Anaplastic astrocytoma and glioblastoma, the most common
primary brain tumours in adults and childhood, are quite
refractory to current treatment with median survival rarely
exceeding 1 year (Holland, 2000). Current first-line treatment for
malignant gliomas is surgery and radiation therapy and/or
chemotherapy. However, p53 mutations, mdm2 amplification/
overexpression, or deletions of the CDKN2A/p14ARF tumour-
suppressor gene often render the gliomas resistant to these
therapeutic approaches (Frankel et al, 1992; Van Meir et al,
1994; Iwadate et al, 1996). Replication-selective oncolytic adeno-
viruses that can replicate in and cause lysis of tumour cells, but
spare normal cells, have been introduced recently as new
therapeutic strategies and are currently evaluated in clinical trials.
We have demonstrated significant antitumour activity of the E1B
55 kDa-gene-deleted, replicative adenovirus ONYX-015 (dl1520,
CI-1042; ONYX Pharmaceuticals) in human malignant glioma
tumour xenografts derived from primary tumours (Geoerger et al,
2002). Although initially suggested to replicate selectively in p53
mutant tumour cells, ONYX-015-mediated cytolysis in our tumour
xenografts was irrespective of cellular p53 status.
Several reports have shown that ONYX-015 is most effective
when combined with conventional anticancer therapies. In this
regard, ONYX-015 has been described to increase chemosensitivity
in vitro and in preclinical in vivo xenograft models (Heise et al,
1997; 2000; Vollmer et al, 1999; You et al, 2000). Clinical phase II
trials combining intratumoral ONYX-015 injection with che-
motherapy cisplatin and 5-fluorouracil in patients with recurrent
head and neck cancer has shown promising results (Khuri et al,
2000). Furthermore, ONYX-015 has been suggested as an effective
neoadjuvant to radiation therapy in a human colon carcinoma
model (Rogulski et al, 2000). Radiation therapy plays the central
role in the current treatment of malignant gliomas. We therefore
investigated the possible radiosensitising effect of ONYX-015 on
malignant glioma cells. The present report provides evidence that
ONYX-015 has an additive, even potentiating antitumour effect on
irradiated human brain tumour xenografts supporting the use of
combined treatment with this attenuated replicative adenovirus
and radiation therapy for malignant gliomas.
MATERIALS AND METHODS
Adenovirus
The chimeric human group C adenovirus ONYX-015 contains a
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encoding the 55 kDa protein and a C-T transition at position
2022 in E1B generating a stop codon at the third codon position of
the protein (Barker and Berk, 1987). These alterations eliminate
expression of the E1B 55 kDa gene in ONYX-015-infected cells. The
virus was generously provided by ONYX Pharmaceuticals (Rich-
mond, CA, USA).
Xenografts and experimental design
Antitumour activity was evaluated against advanced stage human
malignant glioma IGRG88 (p53 mutant) and glioblastoma xeno-
graft IGRG121 (p53 wild-type) derived from primary tumours,
previously described (Geoerger et al, 2002). All animal experi-
ments were carried out with ethical committee approval and under
the conditions established by the European Community (Directive
86/609/CCE) and in accordance with the UKCCCR guidelines
(Workman et al, 1998). Female SPF-Swiss athymic nude mice
bearing s.c. tumours of 100–300 mm3 were randomly assigned to
treatment groups on day 0 of treatment. Tumours were measured
three times weekly and tumour volume calculated according to the
equation: V (mm3)¼width2 (mm2) length (mm)/2. The experi-
ment was stopped after 120 days when there were tumour-free
survivors. Statistical significance between treatment groups and
controls was estimated by the two-tailed nonparametric Kruskal–
Wallis test. Tumour regression was described using standard
terminology. ‘Additive’ antitumour activity was defined as an
antitumour effect of the sum of both agents alone, ‘synergy’ as
effects greater than the sum of both agents alone, and ‘potentia-
tion’ as the effect of an itself nontoxic agent to increase the efficacy
of the combined agent.
Radiation and adenoviral treatment
X-rays were delivered under a tension of 225 kV and 17 mA, using a
filter of 0.5 mmCU with an RT250 Phillips. Total body irradiation
was performed once on day 0 at a dose of 5 Gy (maximum tolerated
dose). Following irradiation, animals were placed in a system with
constant air renewal allowing to perform experiments under L2
conditions. For combined treatment studies, animals bearing
IGRG88 xenografts received 5 Gy TBI and intratumoral injections
of 1 108 PFU ONYX-015 in 50ml PBS for 5 consecutive days.
Animals bearing IGRG121 xenografts, received TBI and a dose of
1 107 PFU ONYX-015 for 5 days. The first virus injection was
performed 6–7 h following irradiation in anaesthetized animals.
Different sites of the tumour were chosen for each injection.
Simultaneously, groups of animals were either irradiated with 5 Gy
and injected with vehicle PBS without glycerol (Gibco Invitrogen
SARL, Cergy Pontoise, France) for 5 days, or were enclosed in a
radiation chamber without radiation and received injections of
1 108 PFU ONYX-015 or 1 107 PFU ONYX-015, respectively, for
5 days, or control animals were enclosed in the radiation chamber
without radiation and were injected with PBS in an equivalent
volume and schedule. Experiments were carried out with ethical
committee approval and under the conditions established by the
European Community (Directive 86/609/CCE) and in accordance
with the UKCCCR guidelines (Workman et al, 1998).
Infectivity using Ad-luciferase
Short-term cultures of IGRG88 and IGRG121 glioma cells (104/well
in a 96-well plate) in triplicate were irradiated with 0, 2, and 5 Gy
and incubated 48 h later with AdCMVLuc at 10 or 100 MOI.
Luciferase activity in the cells was assayed 48 h after infection
using the Luciferase Assay System (Promega, Madison, WI, USA)
and a Lumat LB 9507 luminometer (EG&G Berthold, Bad Wildbad,
Germany). Infectivity of glioma cells was defined by the amount of
luciferase activity measured after adenoviral-mediated gene
transfer in the tumour cells.
Flow cytometry for cell cycle
Subcutaneous IGRG88 and IGRG121 tumours were harvested at
baseline and 7, 24, and 48 h after 5 Gy TBI irradiation treatment
and were frozen at 801C. Tumour cells were aspirated from
frozen tumours with a 25 Gauge needle and resuspended to
approximately 3 106 cell ml1 in Tris buffer, pH 7.6 (100 mM
Trizmas Base, 82 mM HCl, 100 mM NaCl) without further
enzymatic cell-separation step. Cells were stained with propidium
iodide buffer (10 mM NaCl, 3.4 mm trisodium citrate, 0.001%
propidium iodide, 0.1% Nonidet P-40, and 0.005% RNase) for 1 h.
The DNA content of individual cells was measured using a
FACScalibat (Becton Dickinson).
Adenovirus cytopathic effect assay
IGRG121 tumour xenografts were injected in vivo once with
107 PFU ONYX-015 or 108 PFU ONYX-015, or 107 PFU ONYX-015,
7 h after 5 Gy TBI. Experiments were carried out with ethical
committee approval and under the conditions established by the
European Community (Directive 86/609/CCE) and in accordance
with the UKCCCR guidelines (Workman et al, 1998). Tumours
were harvested 1, 3, and 6 days after treatment and stored at
801C. Tumours were grinded on fluid nitrogen and resuspended
in PBS. Virus was released from cells by freeze/thaw cycles. Serial
dilutions on the lysates were titred on the human retinoblast cell
line 911 for cytopathic effect in vitro. Briefly, 104 911 cells per well
were plated in DMEM supplemented with 10% fetal bovine serum
(Gibco Invitrogen SARL, Cergy Pontoise, France) in 96-well plates
and infected after 24 h with the virus solution at end point
dilutions according to standard procedures. Plates were incubated
in humidified conditions at 371C and monitored daily for
cytopathic effect during 14 days. Each sample was done in
triplicate. Uninfected wells were used as a control for cell survival.
Histology and immunohistochemistry for adenoviral
hexon protein
Formalin-fixed paraffin-embedded tumours, cut into 4-mm thick
sections, and rehydrated, were incubated for 1 h at 351C with the
polyclonal antibody AB 1056 (Chemicon International, Temecula,
CA, USA) diluted 1 : 300. Detection was performed by a
biotinylated rabbit secondary antibody to goat immunoglobulin
streptavidin– horseradish peroxidase conjugate (DAKO, Glostrup,
Denmark), and the chromogen diaminobenzidine. Slides were
counterstained with haematoxylin. Haematoxylin –eosin –safranin
staining was performed for morphology; Masson’s trichrome
staining for collagen type I, was performed according to the
manufacturer’s instructions and using aniline blue (Reactifs RAL,
Martillac, France).
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labelling (TUNEL)
Terminal deoxynucleotidyl transferase-mediated dUTP nick end
labelling (TUNEL) was performed to quantify apoptotic cell death
using the In situ Cell Death Detection Kit, AP (Roche Diagnostics
GmbH, Mannheim, Germany) according to the manufacturer’s
instructions. Tissue sections were deparaffinised, rehydrated, and
received microwave pretreatment in citric acid buffer for antigen
retrieval. DNA strand breaks were labelled by polymerisation of
fluorescein-dUTP to the 30-OH sites, catalysed by terminal
deoxynucleotidyl transferase (TdT), revealed by antifluorescein
Fab fragments conjugated with alkaline phosphatase (Converter-
AP), and visualised using Fast Red (DAKO, Glostrup, Denmark).
TdT and dUTP were omitted for negative controls. TUNEL-
positive cells, displaying compaction or segregation of the nuclear
chromatin, or breaking up of the nucleus into discrete fragments,
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were counted per view at  100 magnification. Five representative
fields were chosen for counting; necrotic fields were excluded.
RESULTS
Radiation therapy and ONYX-015 have potentiating
antitumour activity in human malignant glioma xenografts
in vivo
Antitumour activity of ONYX-015 in combination with radiation
therapy in vivo was evaluated in the moderately radiosensitive
human malignant glioma xenografts IGRG121 and IGRG88
deriving from primary tumours. To prevent potential mutagenesis
of adenoviral DNA, irradiation was delivered prior to intratumoral
injections of ONYX-015. Intratumoral administration of ONYX-
015 at 1 108 PFU/injection on 5 consecutive days to mice bearing
advanced stage subcutaneous IGRG88 tumour xenografts resulted
in significant tumour growth delay of 10 days compared to
controls (Po0.05) and one and two out of 10 animals experienced
complete and partial tumour regression, respectively (Table 1,
Figure 1A). Total body irradiation of 5 Gy induced a significant
tumour growth delay of 15 days compared to untreated controls
(Po 0.01). Moreover, combined treatment of irradiation given
6–7 h prior to the first intratumoral ONYX-015 treatment yielded
an additive antitumour activity with 73% partial tumour regres-
sions and TGD of 30 days (Po0.001, compared to untreated
controls) (Table 1, Figure 1A and B).
In the IGRG121 xenografts, intratumoral treatment with ONYX-
015 at 1 108 PFU times 5 has previously been proven highly
effective, inducing 73% tumour-free survivors at 4 months
(Geoerger et al, 2002). To be able to demonstrate additive or even
synergistic effects, the study in this xenograft was conducted with a
decreased dose of 1 107 PFU daily ONYX-015 injections. At this
dosage, ONYX-015 induced neither significant tumour growth delay
nor tumour regression (Table 1; Figure 1C). Total body irradiation
induced a significant tumour growth delay of 11 days compared to
controls (Po0.01). Most importantly, the ‘subtherapeutic’ dose of
ONYX-015 potentiated antitumour activity of total body irradiation
and induced a significant tumour growth delay of 75 days compared
to untreated controls (Po0.001) and 40% partial and 50% complete
tumour regressions with five of 10 animals surviving tumour-free
120 days after treatment (Table 1; Figure 1C and D).
Irradiation does not increase adenoviral infectivity in
malignant glioma cells in vitro
The coxsackie adenoviral receptor (CAR) plays a crucial role in the
viral infection of cells, with av integrins promoting internalisation.
Previously, we have shown expression of CAR in the malignant
glioma tumour IGRG88, but hardly any expression in the highly
ONYX-015-sensitive tumour IGRG121 (Geoerger et al, 2002). To
investigate whether irradiation might sensitise tumour cells to
adenoviral infection through upregulation of receptor expression,
we determined expression of CAR and av integrins after RT in
CAR negative glioma cells in vitro. However, expression of both
receptors was not significantly influenced through prior radiation
treatment (data not shown). In addition, we examined whether
irradiation influences viral infectivity of glioma tumour cells using
an adenovirus vector expressing luciferase under the CMV
promoter. Transgene expression of the IGRG88 and IGRG121
glioma cells in vitro, infected at 10 and 100 MOI, was not increased
48 h after irradiation with 2 or 5 Gy compared to untreated
controls (Figure 2). These observations were further confirmed in
glioma cell lines (U118-MG, U373-MG, Gli-6; data not shown). In
fact, infectivity of IGRG121 was not superior to that of IGRG88,
suggesting that the efficacy in vivo was not determined by infection
efficiency alone.
Radiation therapy does not significantly increase S-phase
fraction, but induces cell cycle arrest
Cellular S-phase fraction has been suggested to determine
sensitivity of cells to viral infection (Goodrum and Ornelles,
1998). To investigate if irradiation facilitates viral infection and/or
replication through a shift of tumour cells into S phase, we
analysed cell cycle status of the subcutaneous IGRG88 and
IGRG121 tumours by FACS at baseline and 7, 24, and 48 h after
5 Gy TBI (Figure 3). As expected, IGRG121 with functional p53
arrested in G0/1 and in G2 M during at least 48 h after irradiation.
P53 mutant IGRG88 cells arrested only in G2 M and not in
G0/1. However, there was only a minor increase in tumour
cells in S phase of 3% (IGRG121) and 5% (IGRG88) after 7 h,
with a subsequent drop to 50% of the initial S fraction. These
minor and transient changes might not be considered significant
enough to explain the potentiating effect of combination treatment
in vivo.
Radiation therapy does not increase adenoviral replication
in IGRG121 in vivo
We next examined whether irradiation increases adenoviral
replication in IGRG121 tumours in vivo. Viral titres of ONYX-
015 in tumours injected once with 107 or 108 PFU ONYX-015 were
increased by 5 and 7 log, respectively, at days 3 and 6 compared to
day 1 after injection, demonstrating significant intratumoral
adenoviral replication in vivo (Figure 4). Viral yields in tumours
were higher following intratumoral injection of 108 PFU ONYX-015
compared to 107 PFU ONYX-015. Nevertheless, virus titres were
Table 1 Antitumour activity of ONYX-015 (intratumoral injection) and radiation therapy in subcutaneous malignant glioma xenografts
Treatment intratumoral n PRa CRb TFSc 5 vol days TGDd days Pe
IGRG88 (mutant p53)
Control PBS 10 0 0 0 12 –
Rx 5 Gyf+PBS 11 0 0 0 27 15 o0.01
ONYX-015 108 PFU day1 5 10 2 1 1 22 10 o0.05
ONYX-015+Rx 5 Gyf+108 PFU day1 5 11 8 0 0 42 30 o0.001
IGRG121 (wild-type p53)
Control PBS 9 0 0 0 6 –
Rx 5 Gyf+PBS 9 0 0 0 17 11 o0.01
ONYX-015 107 PFU day1 5 10 0 0 0 11 5 NS
ONYX-015+Rx 5 Gyf+107 PFU day1 5 10 4 5 5 81 75 o0.001
aPartial regression; bcomplete regression; ctumour-free survival; dtumour growth delay; efor each experiment, the 5 volumes in the treatment groups were compared to those
of the control group using a two-tailed nonparametric Kruskal –Wallis test; ftotal body irradiation.
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not increased through prior radiation treatment in tumours
injected with 107 PFU compared to those treated with adenovirus
alone. In fact, they were slightly lower.
We further performed histology and immunohistochemistry for
adenoviral hexon protein on paraffin-embedded tissue sections of
IGRG121 tumour xenografts treated with 5 Gy TBI and/or five
adenoviral injections. IHC confirmed the findings of viral yields
and showed no increase of adenoviral replication at day 5
(Figure 5M) and day 10 (not shown) in tumours treated with
radiation prior to five times 107 PFU ONYX-015 injections
compared to ONYX-015 alone (Figure 5I). With or without prior
irradiation, adenoviral replication was significantly lower than in
tumours injected with the 10-times higher dose of 108 PFU ONYX-
015 for 5days (Figure 5Q).
Induction of apoptotic cell death is not responsible for the
potentiating effects of ONYX-015 with RT in IGRG121 in
vivo
Since the tumour-suppressor protein p53 mediates cell-cycle arrest
and/or apoptosis in response to oncogenic signals such as E1A and
DNA damage, we determined whether apoptotic cell death might
be a major event in the cytotoxic effect of adenovirus ONYX-015
and in combination treatment with RT. Staining on the tissue
sections of injected xenografts of the p53 functional IGRG121 at
day 5 of ONYX-015 108 PFU 5 treatment revealed major
preapoptotic and apoptotic changes in 3.1% of tumour cells,
Figure 1 Antitumour activity of radiation therapy (5 Gy TBI) and ONYX-015 in p53 mutant IGRG88 and p53 wildtype IGRG121 subcutaneous malignant
glioma xenografts. Mice bearing subcutaneous IGRG88 (A, B) and IGRG121 xenografts (C, D) were randomly assigned to four groups: control animals
injected with PBS (open square&), animals irradiated with 5 Gy TBI (open circleJ), animals injected with ONYX-015 108 PFU day1 5 in IGRG88, and
107 PFU day1 5 in IGRG121 (solid square ’), and animals irradiated with 5 Gy TBI and injected with ONYX-015 108 PFU day1 5 or
107 PFU day1 5, respectively (solid circleK). Panels (A) and (C) give the means of all treatment groups, panels (B) and (D) show the individual tumours
of animals subjected to combination treatment compared to the mean of the controls. Each line represents one individual tumour.
Figure 2 In vitro infectivity of IGRG88 and IGRG121 glioma cells 48 h
after irradiation with 2 and 5 Gy using AdCMV Luciferase. IGRG88 and
IGRG121 glioma cells in short-term cultures were irradiated with 2 Gy
(hatched bars) and 5 Gy (black bars), and infected with the AdCMVLuc
virus at an MOI of 10 and 100. White bars represent nonirradiated
controls. Luciferase activity values represent means of triplicate; error bars
mark the standard deviations.
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displaying compaction or segregation of the nuclear chromatin, or
breaking up of the nucleus into discrete fragments (Figure 5R). In
contrast, no significant increase in apoptotic figures compared to
PBS-injected controls (0.21% TUNEL-positive tumour cells;
Figure 5B) could be determined in irradiated IGRG121 tumours
(0.34% TUNEL-positive tumour cells; Figure 5F), or when treated
with the noneffective, but radiation-potentiating dose of ONYX-
015 107 PFU 5 (0.39% TUNEL-positive tumour cells; Figure 5J),
or the combination of this adenovirus dose with irradiation (0.42%
TUNEL-positive tumour cells; Figure 5N).
ONYX-015 accelerates radiation-induced tumour fibrosis
in vivo
HES staining for morphology revealed an interesting aspect of the
treated xenografts (Figure 5). IGRG121 tumours treated with the
cytotoxic dose of 5 108 PFU ONYX-015 showed at day 10 post-
therapeutic changes, including few viable tumour cells, with
preapoptotic changes and single cell necrosis, surrounded by
stromal fibrosis (Figure 5S and T). IGRG121 tumours treated with
combined radiation therapy and 107 PFU ONYX-015 5 at day 10
revealed few mitotic figures and dystrophic tumour cells
(Figure 5O). Tumour cells in many areas were replaced by stromal
infiltration; small foci of viable tumour cells were surrounded by
fibrosis and inflammatory cells, mainly macrophages and lym-
phocytes. Masson’s trichrome staining determined collagen type I,
stained in blue, as the predominant morphological component of
these fibrotic changes (Figure 5P). Thus, although treatment with
RT and a 10 times lower dose of ONYX-015 induced an antitumour
efficacy comparable to that of the higher virus dose alone
(Geoerger et al, 2002), the cytolytic changes seen after high-dose
adenoviral treatment were replaced by major fibrotic changes
which were much more profound and occurred more rapidly than
in tumours treated with irradiation alone (Figure 5G and H).
DISCUSSION
We described previously the potential of adenoviral therapy using
the replicative E1B-attenuated ONYX-015 (dl1520, CI-1042) in
human malignant glioma models in vivo (Geoerger et al, 2002).
ONYX-015 displayed significant antitumour activity in p53 mutant
IGRG88 and in p53 wildtype IGRG93 and IGRG121 advanced stage
tumours. Interestingly, our wildtype p53 gene sequence tumours
were more susceptible than the p53 mutant tumours experiencing
high rates of tumour regressions and tumour-free survivors. A
phase I clinical trial in recurrent malignant glioma (NABTT-9701)
is currently ongoing. Nevertheless, it is unlikely that adenoviral
therapy applied as a monotherapy will cure glioblastoma. Data
from preclinical studies and clinical trials have suggested that
ONYX-015 sensitises tumour cells to killing by chemotherapy
(Heise et al, 1997; 2000; Vollmer et al, 1999; You et al, 2000) or
radiation therapy (Rogulski et al, 2000). A phase II trial of a
combination of intratumoral ONYX-015 injection with cisplatin
and 5-fluorouracil in patients with recurrent squamous cell cancer
of the head and neck showed substantial objective responses
(Khuri et al, 2000). The mechanisms of interaction between
chemotherapy or ionising irradiation and adenoviral therapy are
not fully elucidated. In addition, the role of p53 in combination
therapy with ONYX-015 has remained largely unresolved. In
combination with cisplatin-based chemotherapy, ONYX-015 has
shown additive or potentially synergistic efficacy in vitro and in
human tumour xenograft model studies in p53-deficient as well as
in p53-functional tumour cells (Heise et al, 1997). In addition,
Vollmer et al. (1999) suggested a more viral dose-dependent rather
than a p53-selective effect of synergistic antitumour activity in
hepatocellular carcinoma models. In contrast, You et al. (2000)
found that the synergistic effect of ONYX-015 and paclitaxel and
cisplatin in lung cancer cells was p53 mutant dependent, and
Rogulski et al. (2000) and colleagues showed that additive effects
of radiation and ONYX-015 in human colon carcinoma were
limited to ONYX-015-sensitive, p53-deficient tumours. Radiation
therapy following surgical resection is the current first-line
treatment strategy for malignant gliomas. The ability of tumour
cells to develop resistance to radiotherapy is, however, a principal
limitation of the current standard treatment. As viral therapy and
radiotherapy act by different mechanisms, it is not unexpected
that cross-resistance mechanisms have not been identified so far.
For these reasons, combination treatment consisting of radiation
therapy and ONYX-015 administration holds promise for
Figure 3 Cell cycle status in IGRG88 (A) and IGRG121 (B) tumour cells
following irradiation treatment. Subcutaneous IGRG88 and IGRG121
tumours were harvested at baseline (white bars) and 7 h (dotted bars),
24 h (horizontal hatched bars), and 48 h (hatched bars) after 5 Gy TBI
irradiation treatment. Aspirated tumour cells were stained with propidium
iodide buffer and DNA content was measured using flow cytometry.
Values represent means of triplicate; error bars mark the standard
deviations.
Figure 4 Adenoviral replication in glioblastoma IGRG121 following RT
and ONYX-015 in vivo. IGRG121 tumours were injected in vivo once with
107 PFU ONYX-015 (white bars), 108 PFU ONYX-015 (hatched bars), or
107 PFU ONYX-015 7 h after 5 Gy TBI (dotted bars) and harvested on
days 1, 3, and 6. Serial dilutions of tumour cell lysates were titred on the
human retinoblast cell line 911 for cytopathic effect. Values represent
means of four or five independent tumours each measured in triplicate;
error bars mark the standard deviations.
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glioblastoma. Here we demonstrate additive, even potentiating
antitumour activity of ONYX-015 in combination with radiation
therapy in two malignant glioma xenograft models in vivo. Both
tumours exhibited similar and moderate sensitivities to 5 Gy
irradiation. In the p53-mutant IGRG88, total body irradiation prior
to ONYX-015 treatment showed additive tumour growth delay
compared to each treatment strategy alone. In the ONYX-015
highly sensitive, p53 functional IGRG121, concomitant therapy at
the same dose of irradiation and ONYX-015 at a 10 times lower
virus dose, which, in itself was ‘subtherapeutic’, resulted in
potentiated tumour growth delays and tumour-free survivors. To
provide some insight into the mechanism of interaction between
irradiation and ONYX-015 in glioma, we investigated the effect of
radiation on ONYX-015 infection and replication in p53 wildtype
and mutant glioma cells in vitro and in vivo.
Group C adenovirus infection is dependent upon the expression
of the primary and secondary receptors CAR and the av integrins
on the target cells for binding and internalisation, respectively
(Bergelson et al, 1997; Tomko et al, 1997). Therefore, we first
investigated if radiation therapy sensitises tumour cells to
Figure 5 Histology of glioblastoma IGRG121 treated with RT and ONYX-015. Immunohistochemical staining of adenoviral hexon protein (A, E, I, M,
Q), terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labelling (TUNEL) (B, F, J, N, R), haematoxilin–eosin–safranin staining (C,
G, K, O, S), and Masson’s trichrome staining in IGRG121 human glioblastoma xenografts treated with PBS (A, B, C, D), 5 Gy TBI (E, F, G, H), ONYX-015
107 PFU day1 5 (I, J, K, L), 5 Gy TBI and ONYX-015 107 PFU day1 5 (M, N, O, P) or ONYX-015 108 PFU day1 5 (Q, R, S, T). Tumours were
excised from nude mice on day 5 (IHC and TUNEL staining) or day 10 (HES and Masson’s trichrome staining) after treatment start. In IHC, nuclei containing
the adenoviral hexon protein are stained brown. Adenoviral replication was not increased after RT (M) compared with ONYX-015 107 PFU day1 5
alone (I). Five 108 PFU ONYX-015 injections induced significant features of apoptotic cell death displaying compaction or segregation of the nuclear
chromatin, or breaking up of the nucleus into discrete fragments ((R), TUNEL-positive cells are stained in red) compared to untreated controls (B).
Apoptotic rate was insignificantly increased 5 days after irradiation treatment of 5 Gy (F), ONYX-015 107 PFU day1 5 (J), and in tumours treated
combined with irradiation and ONYX-015 107 PFU day1 5 (N). ONYX-015 108 PFU day1 5 induced preapoptotic changes and tumour cell necrosis
(S). After 5 Gy TBI and ONYX-015 107 PFU day1 5 cells, foci of viable tumour cells were surrounded by inflammatory cells and prominent fibrosis (O);
collagen type I as marker for fibrosis is stained in blue (P). Hexon IHC and TUNEL were photographed at  100 original magnification, HES and Masson’s
trichrome staining at 50 original magnification.
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adenoviral infection through upregulation of the expression
of adenovirus receptors. Without irradiation, CAR was expressed
on IGRG88, but not on the highly ONYX-015 sensitive IGRG121
cells (Geoerger et al, 2002). Irradiation did not significantly
increase expression of adenoviral receptors in malignant glioma
cells in vitro. In addition, viral infection and gene transfer
efficiency using a luciferase adenovirus vector was not increased
through irradiation in vitro (Figure 2). Thus, irradiation did
probably also not enhance ONYX-015 infection in vivo by
facilitating cell entry.
We next investigated cell-cycle status upon irradiation because
it has been described that cells in the S phase are more sensitive to
lytic activity of adenovirus than those in the G0/1 phase (Goodrum
and Ornelles, 1998). The two tumour xenografts included in this
study differed only little in the percentage of cycling cells per se.
Irradiation induced a transient increase of S-phase fraction of only
3–5% after 7 h, followed by cell-cycle arrest and a subsequent drop
of S-phase fraction to 50% of the initial percentage (Figure 3).
Although transient increase of cycling cells might facilitate
adenoviral infection, the following increase of cells in G0/1 and
G2 M during growth arrest could even decrease their sensitivity
thereafter. Therefore, we concluded that irradiation did not
potentiate ONYX-015 by changing the cell cycle profile.
Next, viral replication of ONYX-015 following irradiation was
evaluated in vivo by measuring quantitatively viral yields in treated
tumours and by immunohistochemistry for adenoviral hexon
protein to visualise virus-infected cells in tumour sections.
Recently, another replication-competent, oncolytic adenovirus,
the prostate cancer-specific CV706, showed substantial synergistic
antitumour efficacy in combination with radiation therapy (Chen
et al, 2001). High-dose irradiation increased viral titres in the
human prostate cancer cell line LNCaP in vitro, but this was
not confirmed in vivo. Surprisingly, we observed that tumours
treated with irradiation and ONYX-015 contained less virus
compared to tumours treated at the same virus dose alone and
much less than tumours injected with the 10-times higher
dose of ONYX-015. Immunohistochemistry confirmed these
findings. We concluded therefore, that irradiation of glioma
tumours does not enhance ONYX-015 infection and replication.
We scheduled our in vivo experiments using 5 Gy TBI followed 6–
7 h later with the first virus injection and observed potentiating
antitumour efficacy. In both previous reports on combined
adenoviral and radiation treatment, however, adenovirus was
given prior to irradiation. Also, these studies showed additive or
synergistic effects. The efficacy of combined radiotherapy and
adenoviral therapy does not seem to be dependent on the
sequencing of both agents, but needs to be further explored
within the same tumour model.
Although ONYX-015 was administered after irradiation, it is still
conceivable that adenovirus replication potentiated radiation-
induced processes. ONYX-015 expresses functional E1A proteins.
Malignant tumours, when expressing adenovirus E1A, are very
sensitive to in vivo treatment with DNA-damaging agents,
including irradiation (Sanchez-Prieto et al, 1995, 1996; 1998;
Martin-Duque et al, 1999). In addition, sensitisation of p53-
functional tumour cells may involve induction of high levels of p53
protein by E1A expression (Lowe and Ruley, 1993). Indeed,
intratumoral ONYX-015 treatment induced significant expression
and stabilisation of the p53 protein in the p53 wild-type IGRG121
tumour (Geoerger et al, 2002). ONYX-015 replication might
therefore induce p53-dependent growth arrest and/or cell death,
additional to radiation-induced effects. The absence activation of
p53 could be one reason for the less evident effect of the combined
treatment in our p53 mutant IGRG88 model. However, there are
many potential differences between tumour cells beside a varying
p53 gene sequence, and a difference in their sensitivity may only be
attributed to p53 unless evaluated in otherwise perfectly matched
cell lines. Moreover, the infectability of p53 wildtype glioma
cells even raises concerns about the implications of this adeno-
virus on normal brain tissue. Nevertheless, tumour cells with
functional p53 are still not ‘normal’ cells. Quiescent or slow
proliferating cells do not sustain the replication of ONYX-015,
however, infection cannot be completely excluded to current
knowledge. Nonattenuated adenoviruses replicate inefficiently
and undergo an abortive infection in mouse and rat tissue cells.
Thus, rodent animal models are not adequate settings to test
toxicity of replication-competent adenoviruses. Definite proof
of safety and efficacy will unfortunately have to await results
from clinical trials with ONYX-015. To date, no significant toxicity
has been reported following intratumoral, intraperitoneal, or
intrahepatic arterial injections into cancer patients in Phase I
and II trials.
IGRG121 tumours treated with the high dose of ONYX-015
(5 108 PFU) showed major post-therapeutic changes, including
apoptosis, single cell necrosis and stromal fibrosis. However, these
changes were not seen in tumours treated with radiation alone or
with radiation and ONYX-015 at the lower dose. In the latter case,
antitumoral effects were primarily associated with infiltrations of
macrophages and lymphocytes, and predominant, early appearing
tumour fibrosis. We therefore suggest, that the potentiating
antitumour activity of radiation therapy and ONYX-015 is related
to an induction of inflammatory processes through adenoviral
infection and subsequent acceleration of radiation-induced
processes of tissue fibrosis.
In summary, our investigations demonstrate the potentiating
antitumour efficiency of local treatment with the E1B-deleted,
replication-competent adenovirus ONYX-015 in combination with
radiation therapy in human glioblastoma xenografts. The combi-
nation treatment was particularly effective on the p53 functional
IGRG121 xenografts. Although it remains to be determined
whether ONYX-015 exerts any toxicity to normal brain tissues,
combination therapy with replication-selective oncolytic viruses
and radiation therapy holds promise as a new treatment paradigm
for glioma.
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